Trading Report: The Vetr Inc. Lowers Illumina Inc. (ILMN) to Hold

The Vetr Inc. Lowers Illumina Inc. (ILMN) to Hold

Vetr lowered shares of Illumina Inc. (NASDAQ:ILMN) from a buy rating to a hold rating in a research report report published on Monday. The firm currently has $187.86 target price on the life sciences company’s stock.

Several other brokerages have also commented on ILMN. Canaccord Genuity set a $136.00 price objective on shares of Illumina and gave the company a hold rating in a research report on Friday, October 7th. CL King lowered shares of Illumina from a buy rating to a neutral rating in a research report on Monday, August 22nd. Zacks Investment Research raised shares of Illumina from a hold rating to a buy rating and set a $190.00 price objective for the company in a research report on Friday, August 26th. Argus raised their price target on shares of Illumina from $175.00 to $185.00 and gave the stock a buy rating in a research report on Monday, August 8th. Finally, Citigroup Inc. raised their price target on shares of Illumina from $175.00 to $190.00 and gave the stock a buy rating in a research report on Monday, September 12th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $157.50.

Illumina (NASDAQ:ILMN) opened at 136.18 on Monday. The company’s 50 day moving average is $172.97 and its 200-day moving average is $156.29. The company has a market cap of $19.96 billion, a price-to-earnings ratio of 46.64 and a beta of 0.47. Illumina has a 12 month low of $127.10 and a 12 month high of $196.47.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.13. The firm earned $600 million during the quarter, compared to analyst estimates of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. Illumina’s revenue was up 11.3% on a year-over-year basis. During the same period last year, the firm posted $0.80 EPS. On average, analysts expect that Illumina will post $3.53 earnings per share for the current fiscal year.

In other Illumina news, Director Jay T. Flatley sold 10,000 shares of the business’s stock in a transaction dated Monday, July 18th. The shares were sold at an average price of $150.00, for a total transaction of $1,500,000.00. Following the sale, the director now directly owns 498,061 shares in the company, valued at $74,709,150. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert S. Epstein sold 300 shares of the business’s stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $170.27, for a total transaction of $51,081.00. Following the sale, the director now owns 7,224 shares in the company, valued at $1,230,030.48. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of ILMN. Tiverton Asset Management LLC acquired a new stake in shares of Illumina during the first quarter worth about $2,372,000. Riverhead Capital Management LLC raised its stake in shares of Illumina by 130.5% in the first quarter. Riverhead Capital Management LLC now owns 11,873 shares of the life sciences company’s stock worth $1,924,000 after buying an additional 6,723 shares during the period. Marsico Capital Management LLC raised its stake in shares of Illumina by 4.8% in the first quarter. Marsico Capital Management LLC now owns 11,898 shares of the life sciences company’s stock worth $1,929,000 after buying an additional 546 shares during the period. State Farm Mutual Automobile Insurance Co. raised its stake in shares of Illumina by 39.5% in the first quarter. State Farm Mutual Automobile Insurance Co. now owns 61,570 shares of the life sciences company’s stock worth $9,981,000 after buying an additional 17,440 shares during the period. Finally, Rafferty Asset Management LLC raised its stake in shares of Illumina by 10.9% in the first quarter. Rafferty Asset Management LLC now owns 5,184 shares of the life sciences company’s stock worth $840,000 after buying an additional 508 shares during the period. Institutional investors own 95.22% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

Related posts

Leave a Comment